
Most Patients With Eosinophilic Asthma on Benralizumab Can Successfully Taper Inhaled Corticosteroids
Patients with severe eosinophilic asthma taking benralizumab may reduce high-dose inhaled corticosteroids/formoterol while maintaining symptom control. After 32 weeks, a reduction of high-dose inhaled corticosteroids/formoterol (HD ICS/F) was …